NEW YORK (GenomeWeb) – Editas Medicine announced Monday that is has closed its initial public offering, raising $97.8 million in net proceeds, including the over-allotment option.

The Cambridge, Massachusetts-based gene editing firm sold 5.9 million shares at the public offering price of $16 per share as well as 885,000 additional shares issued to the underwriters, who fully exercised the over-allotment option.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.